Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on RaxoneŽ (INN: idebenone) in mutliple indications.

Products & Pipeline

Santhera's first product RaxoneŽ has received European marketing authorization in Leber's Hereditary Optic Neuropathy. The compound is also being developed in Duchenne Muscular Dystrophy, and primary Progressive Multiple Sclerosis. Omigapil, a second compound, is in clinical development to treat Congenital Muscular Dystrophy.

Clinical Development Programs

Currently, the NIH are investigating the safety and efficacy of RaxoneŽ in a Phase II trial (IPPoMS) as potential therapy of primary progressive Multiple Sclerosis. Also at the NIH, a Phase I study (CALLISTO) is being conducted to investigate the omigapil in pediatric and adolescent patients suffering from Congenital Muscular Dystrophy.

Latest News

May 03, 2016
Santhera Updates on Regulatory Filings for RaxoneŽ (idebenone) in Duchenne Muscular Dystrophy (DMD)
April 14, 2016
Santhera Co-Sponsors and Presents at the First "Duchenne Pulmonary Outcomes Workshop" Organized by Parent Project Muscular Dystrophy (PPMD)
April 12, 2016
Santhera Reports Increase in Product Sales, Positive Net Result for 2015 and Progress in All Programs